Journal article · 2023 · Open access

Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types

Jammbe Z. Musoro, Corneel Coens, Mirjam A. G. Sprangers, Yvonne Brandberg, Mogens Grøenvold, Hans‐Henning Flechtner, Kim Cocks, Galina Velikova, Linda Dirven, Elfriede Greimel, Susanne Singer, Katarzyna Pogoda and 8 more

European Journal of Cancer, 188, 171–182 · Published 7 May 2023 · DOI 10.1016/j.ejca.2023.04.027

Open PDFView at the publisherCite this paper

In brief

“Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types” is a 2023 journal article by Jammbe Z. Musoro and 19 co-authors, published in European Journal of Cancer. OpenAlex counts 244 citations as of 22 November 2026, which puts it in the top 3% of works published in 2023 by citations. It is open access under a CC BY-NC licence: the full text is free to read at European Journal of Cancer.

Citations
244
Most cited in
2025 (99)
Field-weighted impact
35.52
References
34
Authors
20

Abstract

INTRODUCTION: Early guidelines for minimally important differences (MIDs) for the EORTC QLQ-C30 proposed ≥10 points change as clinically meaningful for all scales. Increasing evidence that MIDs can vary by scale, direction of change, cancer type and estimation method has raised doubt about a single global standard. This paper identifies MID patterns for interpreting group-level change in EORTC QLQ-C30 scores across nine cancer types. METHODS: Data were obtained from 21 published EORTC Phase III trials that enroled 13,015 patients across nine cancer types (brain, colorectal, advanced breast, head/neck, lung, mesothelioma, melanoma, ovarian, and prostate). Anchor-based MIDs for within-group change and between-group differences in change over time were obtained via mean change method and linear regression, respectively. Separate MIDs were estimated for improvements and deteriorations. Distribution-based estimates were derived and compared with anchor-based MIDs. RESULTS: Anchor-based MIDs mostly ranged from 5 to 10 points. Differences in MIDs for improvement vs deterioration, for both within-group and between-group, were mostly within a 2-points range. Larger differences between within-group and between-group MIDs were observed for several scales in ovarian, lung and head/neck cancer. Most anchor-based MIDs ranged between 0.3 SD and 0.5 SD distribution-based estimates. CONCLUSIONS: Our results reinforce recent claims that no single MID can be applied to all EORTC QLQ-C30 scales and disease settings. MIDs varied by scale, improvement/deterioration, within/between comparisons and by cancer type. Researchers applying commonly used rules of thumb must be aware of the risk of dismissing changes that are clinically meaningful or underpowering analyses when smaller MIDs apply.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Musoro, J. Z., Coens, C., Sprangers, M. A. G., Brandberg, Y., Grøenvold, M., Flechtner, H., Cocks, K., Velikova, G., Dirven, L., Greimel, E., Singer, S., Pogoda, K., Gamper, E., Sodergren, S. C., Eggermont, A. M., Koller, M. T., Reijneveld, J. C., TAPHOORN, M. J., King, M. T., & Bottomley, A. (2023). Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. European Journal of Cancer, 188, 171–182. https://doi.org/10.1016/j.ejca.2023.04.027

MLA 9

Musoro, Jammbe Z., et al. “Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.” European Journal of Cancer, vol. 188, 2023, pp. 171–182. https://doi.org/10.1016/j.ejca.2023.04.027.

Chicago

Musoro, Jammbe Z., Corneel Coens, Mirjam A. G. Sprangers, Yvonne Brandberg, Mogens Grøenvold, Hans‐Henning Flechtner, Kim Cocks, et al. 2023. “Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types.” European Journal of Cancer 188: 171–182. https://doi.org/10.1016/j.ejca.2023.04.027.

Harvard

Musoro, J. Z. et al. (2023) ‘Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types’, European Journal of Cancer, 188, pp. 171–182. doi:10.1016/j.ejca.2023.04.027.

IEEE

J. Z. Musoro et al., “Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types,” European Journal of Cancer, vol. 188, pp. 171–182, 2023, doi: 10.1016/j.ejca.2023.04.027.

BibTeX

@article{musoro2023minimally,
  title     = {{Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types}},
  author    = {Musoro, Jammbe Z. and Coens, Corneel and Sprangers, Mirjam A. G. and Brandberg, Yvonne and Grøenvold, Mogens and Flechtner, Hans‐Henning and Cocks, Kim and Velikova, Galina and Dirven, Linda and Greimel, Elfriede and Singer, Susanne and Pogoda, Katarzyna and Gamper, Eva‐Maria and Sodergren, Samantha Claire and Eggermont, Alexander M.M. and Koller, Michael T and Reijneveld, Jaap C. and TAPHOORN, MARTIN J.B. and King, Madeleine Trudy and Bottomley, Andrew},
  journal   = {European Journal of Cancer},
  year      = {2023},
  volume    = {188},
  pages     = {171--182},
  doi       = {10.1016/j.ejca.2023.04.027},
  url       = {https://doi.org/10.1016/j.ejca.2023.04.027}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202355
20244343
20259999
20269797

Its field-weighted citation impact is 35.52: it has been cited 35.52 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life

  • minimally important difference
  • EORTC QLQ-C30
  • cancer-related quality of life
  • anchor-based estimation
  • distribution-based estimation
  • cancer types
  • clinical trials

Work with this paper

Most-cited papers in Economics, Econometrics and Finance

All highly cited Economics, Econometrics and Finance papers

Questions about this paper

How do I cite this paper in APA style?

Musoro, J. Z., Coens, C., Sprangers, M. A. G., Brandberg, Y., Grøenvold, M., Flechtner, H., Cocks, K., Velikova, G., Dirven, L., Greimel, E., Singer, S., Pogoda, K., Gamper, E., Sodergren, S. C., Eggermont, A. M., Koller, M. T., Reijneveld, J. C., TAPHOORN, M. J., King, M. T., & Bottomley, A. (2023). Minimally important differences for interpreting EORTC QLQ-C30 change scores over time: A synthesis across 21 clinical trials involving nine different cancer types. European Journal of Cancer, 188, 171–182. https://doi.org/10.1016/j.ejca.2023.04.027

How many times has this paper been cited?

244 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at European Journal of Cancer: sign in and open the PDF from this page.

Who wrote this paper?

Jammbe Z. Musoro, Corneel Coens, Mirjam A. G. Sprangers, Yvonne Brandberg, Mogens Grøenvold, Hans‐Henning Flechtner, Kim Cocks, Galina Velikova, Linda Dirven, Elfriede Greimel, Susanne Singer, Katarzyna Pogoda and 8 more.

What is the DOI of this paper?

10.1016/j.ejca.2023.04.027, permanently at https://doi.org/10.1016/j.ejca.2023.04.027. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.